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Abstract  
Background: In addition to cost-effectiveness, national guidelines often include other factors to be 
considered in reimbursement decisions. However, weights attached to these are rarely quantified, thus 
decisions may strongly depend on decision makers’ preferences. 
 
Objective: To explore the preferences of policy makers and health care professionals involved in the 
decision-making process for different efficiency and equity attributes of interventions and analyse 
cross-country differences.  
 
Method: Discrete choice experiments (DCEs) were carried out Austria, Hungary, and Norway with 
policy makers and professionals (N=153 respondents). Interventions were described in terms of 
different efficiency and equity attributes (severity of disease, target age of the population and 
willingness to subsidize others, potential number of beneficiaries, individual health benefit, and cost-
effectiveness). Parameter estimates from the DCE are used to calculate the probability of choosing a 
healthcare intervention with different characteristics, and to rank different equity and efficiency 
attributes according to their importance.  
 
Results: In all three countries, cost-effectiveness, individual health benefit and severity of the disease 
are significant and equally important determinants of decisions.  Besides, all countries show 
preferences for interventions targeting young and middle age population compared to those targeting 
population over 65. However, Austria and Hungary show preferences more oriented to efficiency than 
equity, while Norway shows equal weight in preferences for equity and efficiency attributes. 
 
Conclusion: We found that factors other than cost-effectiveness seem to play an equally important role 
in decision making. We also find evidence of some differences in the weight of efficiency and equity 
attributes among countries in the way they prioritize health interventions. 
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In most developed countries reimbursement decisions are based on national guidelines, where cost-
effectiveness of interventions (usually measured as the incremental cost-effectiveness ratio, ICER) 
plays a central role. However, considering factors other than cost-effectiveness also influence real-life 
reimbursement decisions in an effort to better reflect societal preferences. Based on an analysis of past 
reimbursement decisions of the National Institute for Health and Care Excellence (NICE) in the UK, a 
recent study shows that due to other factors entering the decision making process the actual cost-
effectiveness threshold for reimbursement is higher than the stated threshold of £20K–£30K per 
QALY [1]. Such other factors often include potential number of beneficiaries, severity of disease, 
individual health benefit etc are explicitly specified in some reimbursement regulations or 
recommandations [2,3], while the WHO recently proposed a check-list, i.e. Priority Setting in Health 
Care (GPS-Health), for the incorporation of various equity criteria in decision making [4]. However, 
clear guidance of the relative importance of such factors and the weights attached to them rarely 
quantified [1,5]. 
In the absence of rational and transparent approaches to priority setting, decisions are partly made 
based on ad-hoc priority settings [6-9]. With the preferences of those involved in the decision making 
process playing an important role in decisions reached, few studies have attempted to elicit policy 
makers’ preferences for developed countries in recent years [10-13], but without comparative analysis 
to explain differences or similarities in preference  across countries.   
This study aims to contribute to this literature by exploring the preferences of different health care 
actors involved in the decision making process (policy makers, professionals and researchers) for 
different attributes of health care interventions in three European countries: Austria, Hungary and 
Norway. These countries differ greatly in their level of economic development but also in the 
organization of their health care systems. Data from OECD Health Data (2014) place Norway and 
Austria among the countries with the highest health expenditure per capita and health expenditures as 
a proportion of GDP (Norway 4,810 USD PPP and 9.3% of GDP; in Austria 4,033 USD PPP and 
11.1% of GDP), whereas Hungary spends much less on health care both in absolute and relative terms 
(1358 USD PPP and 8.0% of GDP). Regarding the participation of the public sector, Norway has the 
most expanded public healthcare system, with 88% of total healthcare expenditures being public, 
while it is much lower in Austria (76%) and Hungary (63%). At the same time, Norway has a 
decentralized tax-based national health care system with universal coverage under the responsibility of 
both municipalities (primary care) and national governance (specialist care), while Austria follows a 
universal social health insurance (SHI) model and similar to Hungary’s mandatory social health 
insurance mechanism. However, with respect to financing, Hungary is closer to an NHS model, as 
health insurance contributions are administered by a single health insurance payer, i.e. the Health 
Insurance Fund Administration (NHIFA). 
According to Austrian Social Insurance Law (Allgemeines Sozialversicherungsgesetz, 1995) 
reimbursement decisions of the Main Association of Austrian Social Security Institutions and the 
reimbursement recommendations of the Pharmaceutical Evaluation Board, should be based on (a) 
pharmacological analysis (comparison with therapeutic alternatives and perceived degree of 
innovation), (b) medical-therapeutic evaluation (target patient group, effectiveness, expected duration 
and treatment frequency) and (c) economic considerations (including budget impact and PE evidence) 
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[14]. Furthermore, for prescription of drugs falling into the “subsidized only under certain conditions”1 
category the prescribing physicians need to get reimbursement approval from the "head physician" of 
the sickness fund first [15,14].  
In Hungary reimbursement decisions are made by the NHIFA based on recommendation of the Health 
Technology Assessment Committee [3]. Drug-related reimbursement decisions should be based on 
factors such as evidence-based effectiveness and safety, budget-impact, cost-effectiveness of the 
intervention and different aspects related to the disease (i.e. characteristics, size and distribution of 
target population and severity of disease). An explicit priority scoring system to be applied by the 
NHIFA for the evaluation of new hospital medical technologies was developed by the Ministry of 
Health in the decree of Ministry of Health 28/2010 (12/05/2010). The list includes 6 main items2 (with 
15 sub-items)  with quantified weights [16,3,17]. Technologies are to be financed if they receive at 
least 60 points and reach at least 40% of achievable points of all the six criteria. However, 
recommendations and results of appraisals are not publicly available making it difficult to evaluate 
whether the defined criteria are consistently considered during decision making [18,3].  
In Norway the Norwegian Patient Rights Act of 2001 identifies three prioritizing rules for 
reimbursement decisions, (a) the severity of the condition (most need first), (b) expected health 
outcome, and (c) proportionality between need and treatment (using cost-effectiveness analysis) [10]. 
In 2007, the Council for Quality Improvement and Priority Setting was established with advisory 
function in issues pertaining to quality and priorities in the health services [10,19]. 
Through comparative analysis among three European countries, we examine the preferences of 
different health care actors involved in the decision making process regarding equity and efficiency 
attributes of health care interventions using a discrete choice experiment (DCEs). DCEs enable us to 
elicit preferences and quantify the weights of different attributes of health care interventions in 
decision making. The complexity of the discrete choice experiments reflects the multi-dimensional 
real life decisions that policy makers are facing in their daily practice.  
2. Method 
2.1 Discrete choice experiment and design 
DCEs are a frequently used stated preference method where respondents are asked to choose between 
pairs of hypothetical health care interventions [20]. Based on respondents’ choices one can elicit 
preferences, predict probabilities in choosing a given intervention and hence examine the effect that 
changes in intervention characteristics have on choices. In this study, interventions were described in 
terms of different efficiency and equity characteristics (i.e. attributes) that were defined in past studies 
[8,21,22] through two literature reviews [23,24] and adaptations proposed in focus groups of health 
programmers and experts. Following a standardized and validated framework ensured consistency and 
cross-country comparability. Equity attributes consisted of the severity of disease (severe, not severe), 
the target age of the population (young, middle, elderly) and willingness to subsidize others (less or 
more than 70% of the costs are covered by public resources). Efficiency attributes involved the 
potential number of beneficiaries (less or more than 100,000), the individual health benefit of the 
                                                          
1 The Main Association of Austrian Social Security Institutions) based on the recommendations of the 
Pharmaceutical Evaluation Board classify the drugs into different reimbursement categories: red, green and 
yellow boxes. 
2 a, Priorities of the health care system  b, severity of the disease, c, equity (size of the target population, 
accessibility)d, cost-effectiveness and quality of life (ICER, health gain per patient) e, budget impact, f, opinions 
from Hungary and abroad.   
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intervention (less or more than 5 years of full health, the cost effectiveness of the intervention (cost-
effective, not cost-effective), with the threshold of 2 GDP/DALY3. The definition of attributes and 
attribute levels are presented in Table 1. Sawtooth Software was used to select 32 alternatives from the 
full fractional design (96 profiles) which led to 16 pair-wise choices ensuring level balance and near 
orthogonality.  
2.2 Data collection 
The same survey was conducted in all three countries. Surveys were translated in the respective native 
languages (and back translated to verify accuracy) and administered online with potential respondents 
invited to participate either through personal communication, open invitation email or snowballing. In 
all three countries policy makers were primarily targeted: 1) senior staff members at various political 
and legislative decision making levels, and executives of national research and planning institutions 
for health care in Austria; 2) policy makers and professionals at national and regional institutions in 
Hungary4 and 3) senior members of the Norwegian Directorate of Health and senior public health 
academic officials in Norway. In addition, the target population also involved leaders of individual 
health care providers, professionals working in the pharmaceutical industry or consultancy as well as 
researchers and health care academics, whose opinion is potentially/indirectly considered in 
reimbursement decisions. For Austria, direct only invites were sent resulting in a response rate of 15%. 
For Hungary (directed open invites with a target of 50 respondents) and Norway (directed open invites 
and snowballing) make response rate calculation impossible. In total 153 questionnaires were returned 
(Austria: 69, Hungary: 52 and Norway: 32) providing a sufficiently large sample for estimation and 
validity purposes [25].   
2.3 Model 
DCEs are based on random utility theory and respondents choose the intervention that maximizes their 
utility, with utility weights attached to the attributes characterizing the intervention. Assuming a linear 
additive utility and extreme value type I errors conditional logits are estimated [26]. Testing for 
equality of error variances (or scale parameters) to ensure comparability of estimated preference 
weights across the three samples a heteroskedastic conditional logit is fitted [27]. Observed 
heterogeneity is included in the model through two-way interactions of all attributes with individual 
characteristics. The final model specification is determined through backwards selection (at 0.10 
significance level). The significance of unobserved heterogeneity is tested by specifying mixed logits 
with random normally distributed parameters and comparing their fit against conditional logit models 
[28].  
Following estimations, percentage changes in predicted probabilities for each attribute are calculated 
to allow for meaningful comparisons of preferences across attributes and countries [29]. DALY was 
chosen to define the cost-effectiveness threshold in this study, since the same standardized 
questionnaire was used previously in lower and middle income countries such as Brazil, Cuba, Nepal, 
and Uganda [22], where cost-effectiveness thresholds are mostly set by DALYs  [30]. To examine the 
efficiency/equity trade-offs present in decision making and to obtain a measure of their magnitude, 
                                                          
 
4 E.g. National Health Insurance Fund, Ministry of Human Resources, National Institute for Quality and 
Organizational Development in Healthcare and Medicines. 
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purely equitable and purely efficient5 hypothetical interventions are formed and their selection 
probabilities calculated. Taking the ratio of such probabilities and subtracting one provides an 
efficiency/equity ratio with a natural interpretation (i.e. the percentage increase in utility from 
choosing an efficient over an equitable intervention) [12]. The three mutually exclusive levels of age 
of target group necessitate different calculations for each of its levels.  
3. Results 
Descriptive statistics for each sample and overall are given in Table 2. Before moving on the 
estimation results, results from the heteroskedastic logit6 reveal that the assumption of 
homoscedasticity across the three samples holds and hence separability is possible. Similarly, little 
significance is found for unobserved heterogeneity with conditional logits outperforming mixed logits 
according to BIC values.7 Table 3 presents the conditional logit results, while predicted probabilities 
and ratios of predicted probabilities are given in Table 4. 
Looking at each equity attribute in turn, we find Severity of disease to be among the most important 
factor (based on the size of the absolute value of the change in the probability of choosing a given 
profile) in all three countries with interventions targeting severe diseases having increased 
probabilities of selection by 6.9% (95% CI: 3.7 – 10.1), 8.2% (95% CI: 5.0 – 11.4) and 12.1% (95% 
CI: 5.5 – 18.6) for Hungary, Austria and Norway, respectively. Interventions targeting young and 
middle age population are highly preferred over interventions targeting elderly population (over 65), a 
results that holds across all countries. Compared to the base scenario interventions targeting 
populations over 65 are less likely to be chosen by 16.5%, 14.0% and 19.0% in Austria, Hungary and 
Norway, respectively, while the coefficients for interventions targeting middle aged population are all 
insignificant. Willingness to subsidize is significant for Norway, where the high levels of subsidization 
have a positive and significant effect of 7.2%, whereas the corresponding parameter is insignificant for 
Austria and Hungary.  
Regarding efficiency attributes, Individual health benefits and Cost-effectiveness of interventions 
strongly influence respondents’ decisions in all three countries. Changes in probability of selection for 
interventions with large individual health benefits were 13.7%, 8.0%, and 8.9% for Austria, Hungary 
and Norway, while the corresponding values for cost-effective interventions were 8.1%, 8.5%, and 
6.9%, respectively. The average effect of the number of potential beneficiaries is positive and 
significant for Austria (6.8%), but not significant for Hungary and Norway.  
Looking at the interactions with individual characteristics, we find significant differences between 
preferences of different socio-demographic groups. Cross-country patterns do not emerge with the 
exception of cost effectiveness having a relatively higher influence on the decisions of researchers 
compared to those of other stakeholders. Overall, men tend to place a reduced weight for some 
attributes in Austria and Hungary. Respondents’ age (and through this their experience) is found to be 
influential only for Norway, where severity and willingness to subsidize others are less important in 
decision making for respondents under 40. Moving onto respondents’ occupation, we find significant 
heterogeneity in preferences. In Hungary, respondents from the pharmaceutical industry and 
consultancy value cost-effectiveness, and subsidized interventions targeting high number of potential 
                                                          
5 Purely equitable and purely efficient interventions are those where all equity attributes are set to one (with all 
efficiency attributes to zero) and those where all efficiency attributes are set to one (with all equity attributes to 
zero), respectively.  
6 Results are available from the authors upon request.  
7 Results are available from the authors upon request. 
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beneficiaries more than policy makers. Researchers place more weight on severity in Hungary and less 
weight on willingness to subsidize others in Norway, while healthcare professionals assign less weight 
on severity than policy makers in Austria.  
The lower half of Table 4 presents the efficiency/equity ratios. Austria and Hungary have a clear 
preference for efficiency over equity while for Norway such distinction is much less pronounced with 
the two being almost equally important for healthcare actors. For example, in Austria and Hungary the 
probability of choosing the “purely efficient profile” is 47.7% and 37.4% higher than choosing the 
“purely equitable profile” for interventions targeting young population, while in Norway a difference 
of 7.4% is not statistically significant. The same stands for interventions targeting middle aged 
populations. Further, equity seems to be relatively more important when considering interventions for 
young than for elderly population in all the three countries. The probability of choosing the purely 
efficient profile compared to the purely equitable profile is higher for interventions targeting the 
elderly populations than for interventions targeting the young population (i.e. 90.4% vs. 47.7% in 
Austria, 71.8% vs. 37.4% in Hungary and 16.9% vs. 7.4% in Norway). However the equity/efficiency 
ratio for the elderly targeting interventions is estimated with a lot of uncertainty implying insignificant 
differences. 
4. Discussion and conclusion 
The need for achieving efficiency gains (either due to scarcity of resources or to control increasing 
health expenditure) have underlined the need for priority setting even in developed high-income 
countries. Although national guidelines potentially include a number of attributes to be considered 
during the decision making process, currently no methodology is available to order preferences and 
help policy makers choose those interventions mostly preferred by the society. The weights attached to 
different intervention attributes are rarely quantified in guidelines, which results in ad-hoc decisions 
by decision makers  [8,1]. This paper offers a comparative analysis of efficiency and equity 
preferences of decision makers from three European countries (Austria, Hungary and Norway) with 
different health care systems. 
Cross-country comparisons have been missing from the literature with most studies focusing on league 
tables of interventions [10,12]. Although different estimates are obtained for each country in our study, 
some generalizable results also emerge. Interventions targeting the elderly are less favoured compared 
to interventions targeting young and middle age populations. Similar conclusions were reached in 
previous studies focusing on both general population or policy makers as well, e.g. [8,31]. Further, for 
all three countries, equity attributes seem to be relatively more important when considering 
interventions targeting the young population than interventions targeting elderly.  
Cost-effectiveness, individual health benefit and severity of disease are significant and equally 
important determinants of decisions, justifying the need for factors other than cost-effectiveness to 
also be taken into account in reimbursement decisions. On the other hand, size of target population has 
relatively small influence on choices contradicting priority settings guidelines which often consider 
this as an important factor. Willingness to subsidize others is revealed as a significant influence only 
for Norway, where the share of public financing in total health care expenditure is the highest among 
the three countries. 
Furthermore, there is some heterogeneity in preferences according to the respondents’ background, 
with policy makers placing lower weight on cost-effectiveness of an intervention in Hungary and 
Norway compared to other healthcare actors. Such discrepancies in preferences are important to 
consider, as might lead to a lack of consensus in financial decisions.  
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Finally, we quantify the presence of equity and efficiency attributes in preferences of healthcare 
actors. Although more research is needed in this area, significant relationships between health care 
systems and preferences for efficiency and equity are observed. With Austria and Hungary closer 
culturally, geographically and in terms of health systems structure showing preference towards 
efficiency, whereas Norway, with a tax-based national health care system displays a balanced 
preferences for both, efficiency and equity. Our findings confirm recent Hungarian guidelines which 
put relatively more weight on attributes considered as ‘efficiency attributes’ (e.g. incremental cost-
effectiveness ratio, individual health benefit and size of target patient population together represent 
38% of the maximum attainable score compared to severity of the disease, which is only 15% of the 
total scores) [3].  
Our analysis is not exempt of limitations. Our samples are potentially not representative of the health 
policy maker, health professional and researcher populations in the three countries. However, to make 
underlying preference more explicit and condition of potential socio-economic differences observed 
heterogeneity (by age, sex and occupation) was incorporated. For Hungary, compared to Austria and 
Norway, the sample did not include healthcare professionals but professionals from the 
pharmaceutical industry and consultancy, which might be a reason behind the stronger preferences for 
efficiency attributes in Hungary. Small differences in the data collection methods for the three 
countries (snow-ball technique in Hungary and Norway vs directed invitations in Austria) might 
weaken comparability across samples, although formal testing showed lack of heteroskedasticity 
mitigating such concerns. Further, our design has necessary underlying assumptions of independence, 
comprehensiveness and exclusiveness of the selected criteria which however is potential restrictive as 
additional relevant attributes are identified in real-life settings. 
In conclusion, it is crucial to explore decision makers’ preferences, as in the absence of explicit 
priority setting guidelines, these might strongly influence reimbursement decisions. We find that 
factors other than cost-effectiveness (e.g. the severity of the disease, the target age of the population, 
or the size of the individual health) also play an equally important role in decision making. We also 
find evidence of some differences in the weight of efficiency and equity attributes among countries in 
the way they prioritize health interventions. However further research is needed to compare decision 
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Table 1 DCE Attributes and levels 
Attribute  Level Definition 
Severity of disease 
Not severe 
Life expectancy without the intervention > 2 years without 
intervention 
Severe 
Life expectancy without the intervention < 2 years without 
intervention 
   
Number of potential 
beneficiaries 
Few Intervention would reach < 100,000 individuals  
Many Intervention would reach > 100,000 individuals  
   
Age of target group 
Young Intervention target age group between 0 and 14 years old 
Middle-age  Intervention target age group between 15 and 59 years old 
Elderly Intervention  target age group older than 60 years old 
   
Individual health benefits 
Small Intervention produces > 5 years of healthy life per individual 
Large Intervention produces < 5 years of healthy life per individual 
   
Willingness to subsidize 
< 70% 
< 70% of healthcare services expenditures covered through 
subsidies 
> 70% 
> 70% of healthcare services expenditures covered through 
subsidies 
   
Cost-effectiveness 
Not C-E cost per DALY > GDP per capita  







Table 2 Descriptive statistics 
 Austria  Hungary  Norway  Total 
Male 45 (65.2%)  21 (40.4%)  14 (43.8%)  80 (52.3%) 
Age         
    Below 40 12 (17.4%)  21 (40.4%)  15 (46.9%)  48 (31.4%) 
    40 or older 57 (82.6%)  31 (59.6%)  17 (53.1%)  105 (68.6%) 
Group        
    Policy maker 34 (49.3%)  22 (42.3%)  13 (40.6%)  69 (45.1%) 
    Researcher 19 (27.5%)  6 (11.5%)  12 (37.5%)  37 (24.2%) 
    Health care worker 16 (23.2%)  -  7 (21.9%)  23 (15.0%) 
    Industry -  24 (46.2%)  -  24 (15.7%) 






Table 3 Conditional logit estimation results with individual characteristics interactions 
Attributes\countries Hungary  Austria  Norway 
Equity criteria       
































Efficiency criteria      
























Interactions      
Severity of disease * Male -0.394* 
(0.226) 
 -  - 
Age of target group: Middle * Male -  -0.555*** 
(0.173) 
 - 
Individual health benefits * Male -  -0.660*** 
(0.214) 
 - 
Number of potential beneficiaries * Male -0.521*** 
(0.197) 
 -  - 
Cost-effectiveness * Male -0.859*** 
(0.261) 
 -   
Severity of disease * Age(respondent)<40 -  -  -0.640*** 
(0.245) 
Willingness to subsidize others * Age(respondent)<40 -  -  -0.434* 
(0.259) 
Number of potential beneficiaries * Industry 0.519*** 
(0.187) 
 -  - 
Willingness to subsidize others *Industry 0.561*** 
(0.175) 
 -  - 
Cost-effectiveness * Industry 0.625** 
(0.285) 
 -  - 
Severity of disease * Researcher 0.968** 
(0.385) 
 -  - 
Willingness to subsidize others * Researcher -  -  -0.459* 
(0.235) 
Cost-effectiveness * Researcher 1.093*** 
(0.381) 
 -  1.184*** 
(0.389) 
Severity of disease * Health care worker -  -0.623*** 
(0.174) 
  
Number of respondents 52  69  32 
Number of observations 1658  2208  1024 
LogLikelihood -400.51  -578.46  -249.89 
Pseudo-R2 0.3030  0.244  0.296 
Wald Chi2 118.97***  120.88***  63.68*** 




Table 4 Predicted probabilities and the effects of attribute level changes on predicted probabilities 
 Hungary Austria Norway 
 Pr (st.err) %Δ to base [95% CI] Pr (st.err) %Δ to base [95% CI] Pr (st.err) %Δ to base [95% CI] 
Base case (at mean) 79.5% (4.1%) - 74.9 (3.5)% - 74.4% (4.4%) - 
 
Equity attributes 
      
Severity of disease 85.0% (3.4%) 6.9%  [3.7 10.1] 81.1% (3.1%) 8.2%  [5.0 11.4] 83.4% (3.5%) 12.1% [5.5 18.6] 
Age of target group: Middle  84.7% (3.9%) 6.6%  [3.7 9.5] 81.4% (3.1%) 8.7%  [3.9 13.5] 77.4% (6.1%) -4.0% [-3.7 11.7] 
Age of target group: High  68.3% (6.9%) -14.0%  [-22.7 -2.0] 62.5% (6.1%) -16.5%  [-25.7 -7.3] 60.3% (8.1%) -19.0% [-33.5 -4.5] 
Willingness to subsidize others (High level) 77.4% (5.3%) -2.6%  [-6.9 1.7] 74.6% (4.4%) -0.4% [-4. 3.4] 79.8% (4.2%) 7.2% [0.2 14.1] 
Efficiency attributes       
Number of potential beneficiaries (Many)  81.6% (3.8%) 2.6% [-0.9 6.1] 80.2% (3.2%) 6.8% [4.3 9.4] 76.7% (4.7%) 3.1% [-0.7 6.8] 
Individual health benefits (Large)  85.9% (2.8%) 8.0% [4.0 12.1] 85.2% (2.6%) 13.7% [9.4 18.0] 81.0% (3.5%) 8.9% [4.2 13.5] 
Cost-effectiveness (Cost-effective)  86.2% (3.3%) 8.5% [4.2 12.7] 81.0% (3.3%) 8.1% [6.4  9.9] 79.6% (5.0%) 6.9% [3.4 10.4] 
       
Equity/efficiency trade-off Pr (st.err) 
Pr(eff)/Pr(eq)-1 
[95% CI] Pr (st.err) 
Pr(eff)/Pr(eq)-1 
[95% CI] Pr (st.err) 
Pr(eff)/Pr(eq)-1  
[95% CI] 
Young       
Equity profile 65.5% (6.5%)  62.1% (4.6%)  79.0% (%)  
Efficiency profile 90.0% (2.1%) 37.4% [13.6% 61.2%] 91.6% (1.6%) 47.7% [27.  68.2] 84.9 % (3.4%) 7.4%  [-4.5 19.3] 
Middle-aged       
Equity profile 69.6% (9.2%)  67.5% (6.5%)  74.3% (7.7%)  
Efficiency profile 91.6% (2.5%) 31.7%  [3.2% 60.1%] 93.2% (1.3%) 38.2% [14.1 62.3] 81.1% (6.8%) 9.2% [-8.9 27.4] 
Elderly        
Equity profile 47.1% (10.7%)  44.2% (7.0%)  56.1% (7.9%)  
Efficiency profile 80.9% (4.8%) 71.8% [-5,8% 149,5%] 84.2% (4.0%) 90.4% [19.0 161.8] 65.6% (10.9%) 16.9% [-21.8 55.5] 
Note: Significant variables (p value < 0.10) are in bold. Standard errors were calculated by bootstrapping. The effect of changing on attribute level on the probablilites of 
choosing a profile is calculated compared to the base scenario, where all attribute levels are set to the mean, while in the alternative scenario, the given attribute level is set to 1, 
while the others kept at mean.  For the calculation of equity-efficiency ratio we compare the probability of choosing the pure efficient scenario (where all efficiency attributes are 
set to 1 and all equity attributes are set to 0) to the probability of choosing the pure equity scenario (where all efficiency attributes are set to 0 and all equity attributes are set to 
1). 
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